OakChart

Adc Therapeutics SA

ADCTHealthcare·Drug Manufacturers - Specialty & Generic·Switzerland·Micro·NYSE·Nov 11 • 5:39 AM ET

1.53+0.02 (1.32%)
2026-11-11 14:44 CET
Market cap
192.78 USD m
Revenue, TTM
84.87 USD m
Net income, TTM
-81.25 USD m
Free cash flow, TTM
-99.03 USD m
EPS diluted, TTM
-0.53
P/E
-
Compare

Price

ADCT against its 20, 50 and 200-day averages
2050200beat
1.002.003.004.006.3M12.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ADCTclose 1.5320-day 1.5450-day 1.39200-day 2.401.53

69.3% under 4.98 on 11 Mar 2026. Last 15 sessions, 32.7% high to low

Profile

ADCT
52-week range, 18% of the way up
0.784.98

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

IndexRUT
Employees193
IPOMay 15, 2020
Beta1.80
ATR, 14d0.16
Rel volume0.00
Short float6.49%
Insider own22.42%
Inst own61.97%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap195.33M
Enterprise Value122.23M
Income-81.25M
Sales84.87M
Book/sh-1.95
Cash/sh1.48
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees193
IPOMay 15, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S2.30
P/B-
P/C1.03
P/FCF-
EV/EBITDA-
EV/Sales1.44
Quick Ratio2.98
Current Ratio3.05
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.53
EPS next Y-0.64
EPS next Q-0.17
EPS this Y37.72%
EPS next Y7.89%
EPS next 5Y31.56%
EPS past 3/5Y17.66% 21.50%
Sales past 3/5Y-27.09% -
EPS Y/Y TTM63.71%
Sales Y/Y TTM12.85%
EPS Q/Q45.77%
Sales Q/Q32.20%
EarningsNov 09 BMO
EPS/Sales Surpr.24.71% 16.13%

Ownership

Insider Own22.42%
Insider Trans0.00%
Inst Own61.97%
Inst Trans-0.85%
ROA-29.78%
ROE-
ROIC-
Gross Margin88.37%
Oper. Margin-95.17%
Profit Margin-95.73%
SMA20-0.87%
SMA5010.36%
SMA200-36.24%
Trades-

Technical

Shs Outstand127.74M
Shs Float99.04M
Short Float6.49%
Short Ratio3.89
Short Interest6.43M
52W High4.98 -69.28%
52W Low0.78 96.25%
Volatility14.37% 11.11%
ATR (14)0.16
RSI (14)50.92
Beta1.80
Rel Volume0.00
Avg Volume1.65M
Volume237

Performance

Perf Week-11.05%
Perf Month-10.00%
Perf Quarter45.71%
Perf Half Y-56.03%
Perf YTD-56.66%
Perf Year-61.46%
Perf 3Y225.53%
Perf 5Y-94.51%
Perf 10Y-
Recom2.20
Target Price2.62
Prev Close1.51
Price1.53
Change %1.32%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Jun 08, 2026DowngradeHH.C. WainwrightBuy → Neutral
Jun 04, 2026DowngradeRRBC Capital MktsOutperform → Sector Perform$2+30.7%
Nov 08, 2024InitiatedSStephensOverweight$6+292.2%
May 30, 2024InitiatedCCantor FitzgeraldOverweight
Mar 28, 2024InitiatedGGuggenheimBuy$11+619.0%
Aug 10, 2023UpgradeJJP MorganUnderweight → Neutral
Apr 24, 2023DowngradeBBofA SecuritiesNeutral → Underperform$7 → $2+30.7%
Dec 06, 2022InitiatedCCapitalOneOverweight$12+684.3%
Nov 09, 2022DowngradeBBofA SecuritiesBuy → Neutral$14 → $7+357.5%
Sep 21, 2022InitiatedJJP MorganOverweight$5+226.8%

Peers

Mkt cap
TickerCompanyMkt cap
STROSutro Biopharma Inc168.63M
PYXSPyxis Oncology Inc194.96M
AUTLAutolus Therapeutics plc ADR353.59M
ZYMEZymeworks BC Inc2.22B
CTMXCytomX Therapeutics Inc433.83M
GMABGenmab ADR32.45B
CMPXCompass Therapeutics Inc156.67M
ONCBeOne Medicines Ltd ADR44.64B
GERNGeron Corp626.20M
KURAKura Oncology Inc730.36M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Redmile Group, LLC10% OwnerApr 02 '26Sale3.282,634,5068,638,54512,666,731Apr 02 09:00 PM
Redmile Group, LLC10% OwnerApr 02 '26Sale3.282,529,4918,294,20110,265,297Apr 02 09:00 PM
Redmile Group, LLC10% OwnerMar 31 '26Sale3.75196,229736,25115,470,502Apr 02 09:00 PM
Redmile Group, LLC10% OwnerMar 31 '26Sale3.75188,407706,90312,957,305Apr 02 09:00 PM
Redmile Group, LLC10% OwnerApr 01 '26Sale3.80169,265643,03815,301,237Apr 02 09:00 PM
Redmile Group, LLC10% OwnerApr 01 '26Sale3.80162,517617,40212,794,788Apr 02 09:00 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 78.30B
IWNiShares Russell 2000 Value ETFAUM: 14.17B
IBBiShares Biotechnology ETFAUM: 11.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
IWCiShares Micro-Cap ETFAUM: 1.23B
IWOiShares Russell 2000 Growth ETFAUM: 14.20B
GWXState Street SPDR S&P International Small Cap ETFAUM: 897.36M
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.30B
RSSLGlobal X Russell 2000 ETFAUM: 1.44B
IWViShares Russell 3000 ETFAUM: 20.40B

News

latest 14 of 206
  • ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates (PR Newswire) +5.70%
  • ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA Clinical Program (PR Newswire) +10.97%
  • ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
  • ADC Therapeutics Announces New Employee Inducement Grant (PR Newswire)
  • ADC Therapeutics Must Show Lotus 7 Can Carry The Story After Lotus 5's FDA Setback (Earnings Whispers)
  • Loading…
  • ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 (PR Newswire)
  • ADC Therapeutics Announces ZYNLONTA Updates in Japan (PR Newswire) -8.02%
  • ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements (PR Newswire) +11.97%
  • These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch) +6.67% +9.82%
  • ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference (PR Newswire)
  • ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... (GuruFocus.com) -14.63%
  • ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates (PR Newswire)
  • Earnings To Watch: ADC Therapeutics SA (ADCT) Q2 2026 -- GF Value Sees 125% Upside (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.160-0.213-0.16021.7218.704
2026Q22026-08-13-0.110-0.216-0.10719.2518.895
2026Q12026-05-04-0.210-0.202-0.21420.8519.996
2025Q42026-03-10-0.040-0.268-0.04323.0622.306
2025Q32025-11-10-0.300-0.363-0.30016.4316.796
2025Q22025-08-12-0.500-0.492-0.49818.8417.865
2025Q12025-05-14-0.360-0.403-0.36023.0317.716
2024Q42025-03-27-0.290-0.412-0.29216.9119.016
2024Q32024-11-07-0.420-0.395-0.42018.4618.436
2024Q22024-08-06-0.380-0.457-0.38217.4118.897
2024Q12024-05-06-0.560-0.556-0.56518.0518.046
2023Q42024-03-13-1.030-0.502-1.03316.7915.315
2023Q32023-11-07-0.580-0.634-0.58114.4915.155
2023Q22023-08-08-0.580-0.700-0.57819.2820.256
2023Q12023-05-09-0.740-0.020-0.73518.9520.121
2022Q42023-02-28-0.300-0.483-0.30069.8039.383

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-2.690-3.528-3.7650.001.29
2021FY-3.000-3.441-2.99733.9233.01
2022FY-1.990-2.070-2.011209.91187.67
2023FY-2.940-2.394-2.93869.5668.07
2024FY-1.620-1.690-1.62570.8472.66
2025FY-1.120-1.405-1.12081.3680.57
2026FY--0.698--80.45
2027FY--0.643--96.96
2028FY--0.359--191.64
2029FY-0.117--272.18
2030FY-0.304--308.31

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0940122.0018.5028.47
2026Q4S2026-11-0440121.9718.5028.47
2026Q4S2026-10-2740121.9818.5028.47
2026Q4S2026-10-0740221.9818.5028.47
2026Q4S2026-09-1940122.3518.5028.47
2026Q4S2026-09-1340222.3518.5028.47
2026Q4S2026-08-1650222.0818.5028.47
2026Q4S2026-08-1350322.0818.5028.47
2026Q4S2026-07-1850222.3018.5028.47
2026Q4S2026-07-0651222.3018.5028.47
2026Q4S2026-06-2352122.3518.5028.47
2026Q4S2026-06-0952122.3518.5028.47
2026Q4S2026-06-0562221.9518.5028.47
2026Q4S2026-06-0362221.9418.5028.47

Estimate history

EPS, annual-1.304-1.787-1.742-3.765-2.997-2.011-2.938-1.625-1.122-0.5262
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.42-0.292-0.36-0.498-0.3-0.043-0.214-0.107-0.163
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.8031.142.34033.917209.90869.55870.83781.35784.87
Period201720182019202020212022202320242025TTM
Sales, quarterly18.46416.9123.03318.83916.42723.05820.85119.24821.716
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual68.89368.89366.87276.72276.8180.64382.29398.861125.749127.738
Period201720182019202020212022202320242025MRQ
Shares, quarterly96.68898.86199.178112.499112.627125.749127.165127.438127.738
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue84.8781.3670.8469.56209.9133.920.002.341.14
Cost of Goods Sold Incl. D&A9.877.679.235.805.693.971.97--
Gross Profit75.0073.6861.6163.76204.2229.94-1.97--
Selling, General and Administrative Excl. Other155.77182.06192.27228.14325.40291.30216.49118.44126.34
Research and Development70.27104.01109.63127.13186.46155.53139.71104.62117.74
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-80.77-108.38-130.65-164.38-121.18-261.35-218.46-117.74-125.71
Interest Expense52.6051.6350.2146.3336.7318.494.930.160.00
Unusual Expense-34.80-9.09-11.47-3.86-8.28-34.8947.200.000.23
Net Income Before Taxes-81.76-142.78-157.20-196.35-147.17-244.83-270.33-115.90-122.87
Income Taxes-0.51-0.16-0.9038.17-0.13-21.480.330.580.22
Consolidated Net Income-81.25-142.62-157.85-240.05-157.13-230.03-246.29-116.48-123.10
Net Income From Continuing Operations-81.25-142.62-157.85-240.05-157.13-230.03-246.29-116.48-123.10
Net Income-81.25-142.62-157.85-240.05-157.13-230.03-246.29-116.48-123.10
EPS (Recurring)-0.68-1.17-1.71-2.97-2.08-3.32-3.26-1.74-1.78
EPS (Basic, Before Extraordinaries)-0.53-1.12-1.62-2.94-2.01-3.00-3.77-1.74-1.79
EPS (Diluted)-0.53-1.12-1.62-2.94-2.01-3.00-3.77-1.74-1.79
EBITDA-80.54-106.50-127.38-161.11-118.79-258.72-216.49-116.10-125.20
Non-Operating Income (Expense)16.828.1412.1910.492.460.120.262.003.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.926.655.1910.6638.9651.5136.560.920.39
Price To Sales Ratio2.235.512.731.951.4345.71---
Gross Margin88.3790.5786.9891.6797.2988.29---
Operating Margin-95.17-133.21-184.44-236.32-57.73-770.57--5,031.79-11,027.54
Net Margin-95.73-175.31-222.83-345.11-74.86-678.20--4,977.95-10,797.89
Shares Outstanding127.74125.7598.8682.2980.6476.8176.7266.8768.89
Market Capitalization192.78192.78192.41133.87295.341,549.882,455.682,451.84-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue21.7219.2520.8523.0616.4318.8423.0316.91
Cost of Goods Sold Incl. D&A1.982.353.731.811.321.682.862.16
Gross Profit19.7416.9017.1221.2515.1017.1620.1714.75
Selling, General and Administrative Excl. Other34.1539.6042.3739.6645.7048.2248.6447.18
Research and Development14.7417.3319.8818.3326.8030.0928.9327.10
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-14.41-22.70-25.25-18.41-30.59-31.06-28.46-32.44
Interest Expense13.7313.5112.3513.0113.3913.0012.2311.92
Unusual Expense1.16-11.69-2.23-22.040.3813.090.00-10.45
Net Income Before Taxes-25.30-16.53-32.97-6.96-41.23-55.87-38.72-31.28
Income Taxes0.000.040.00-0.55-0.270.77-0.12-0.55
Consolidated Net Income-25.30-16.57-32.97-6.41-40.97-56.65-38.60-30.73
Net Income From Continuing Operations-25.30-16.57-32.97-6.41-40.97-56.65-38.60-30.73
Net Income-25.30-16.57-32.97-6.41-40.97-56.65-38.60-30.73
EPS (Recurring)-0.16-0.16-0.22-0.15-0.30-0.42-0.36-0.36
EPS (Basic, Before Extraordinaries)-0.16-0.11-0.21-0.04-0.30-0.50-0.36-0.29
EPS (Diluted)-0.16-0.11-0.21-0.04-0.30-0.50-0.36-0.29
EBITDA-14.41-22.70-25.13-18.30-30.47-30.22-27.66-31.64
Non-Operating Income (Expense)4.007.992.402.433.131.271.982.63
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.094.772.541.531.581.431.912.20
Price To Sales Ratio2.232.087.306.527.263.951.992.96
Gross Margin90.8887.8082.1292.1491.9591.1087.5787.20
Operating Margin-66.37-117.94-121.07-79.85-186.23-164.85-123.58-191.82
Net Margin-116.52-86.06-158.11-27.80-249.38-300.68-167.59-181.71
Shares Outstanding127.74127.44127.17125.75112.63112.5099.1898.86
Market Capitalization192.78136.09476.42437.29450.00265.80139.71192.41

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments261.34250.87278.60326.44466.54439.19115.55138.81262.75
Short Term Receivables29.1220.3225.1872.9731.062.691.991.711.93
Inventories4.1818.3916.1812.0711.120.000.000.000.00
Other Current Assets11.7017.8216.3323.5016.468.565.071.560.49
Total Current Assets306.33307.39336.29434.98525.18450.45122.61142.08265.17
Net Property, Plant & Equipment1.3013.4316.1310.2611.234.766.271.541.14
Total Investments and Advances0.000.001.657.6141.2447.910.000.000.00
Intangible Assets---14.3613.5810.188.436.675.40
Deferred Tax Assets0.79-0.0037.1026.05----
Other Assets15.521.160.710.900.690.400.370.260.23
Total Assets323.94321.98354.78490.86617.97513.69137.68150.56271.95
Short Term Debt Incl. Current Port. of LT Debt3.541.371.471.107.604.631.130.000.00
Accounts Payable9.1818.0315.5712.3512.080.003.336.757.62
Income Tax Payable---0.003.750.150.050.190.16
Other Current Liabilities57.4561.0750.6368.4950.5035.6515.4315.4112.77
Total Current Liabilities70.1680.4767.6781.9473.9440.4419.9422.3520.55
Long Term Debt436.01121.63122.91116.28132.09110.453.900.000.00
Provision for Risks Charges0.000.000.000.003.653.542.681.391.08
Deferred Tax Liabilities0.79--------
Other Liabilities2.81322.53312.45213.19242.2023.760.000.571.16
Total Liabilities509.77524.62503.03411.41451.88178.1926.5324.3222.78
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-185.83-202.64-148.2579.45166.09335.50111.16126.24249.17
Total Shareholders Equity-185.83-202.64-148.2579.45166.09335.50111.16126.24249.17
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-185.83-202.64-148.2579.45166.09335.50111.16126.24249.17
Total Liabilities & Stockholders Equity323.94321.98354.78490.86617.97513.69137.68150.56271.95
Book Value Per Share-1.48-2.05-1.800.992.164.371.661.833.62
Tangible Book Value Per Share-1.48-2.05-1.800.991.994.241.541.743.54
Full-Time Employees193265162317312208127--
Price to Book Ratio-0.77-1.12-2.472.829.347.326.52--
Return on Assets-44.16-46.65-54.31-28.34-40.65-75.62-80.82-58.32-
Return on Equity----127.99-91.72-110.28-98.13-65.65-
Return on Invested Capital-57.01---80.28-77.14-55.23-101.24-97.51-36.07
Quick Ratio4.313.594.735.166.9511.146.156.3612.91
Current Ratio4.373.824.975.317.1011.146.156.3612.91

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-78.34-142.62-157.85-240.05-157.13-230.03-246.29-116.48-123.10
Depreciation-1.883.283.272.392.631.971.650.51
Other Funds (Non Cash)-2.0024.9326.9136.7366.7840.5663.231.140.74
Funds from Operations-80.25-115.82-127.66-162.96-89.59-212.89-181.09-113.70-121.84
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-18.76-25.363.8344.27-48.73-20.4912.36-7.880.48
Cash from Operating Activities-99.01-141.17-123.84-118.69-138.31-233.38-168.73-121.58-121.36
Capital Expenditures-0.03-0.26-0.87-3.22-0.69-6.38-2.81-2.15-2.47
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.680.660.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.00-0.30-0.02-0.10-0.04
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.660.40-0.87-3.22-0.69-6.67-2.83-2.25-2.51
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock59.22152.4698.220.775.910.78433.21101.51-0.02
Repurchase of Common Pref Stock0.000.000.000.00-0.220.000.00-0.14-0.02
Sale of Common Pref Stock59.22152.4698.220.776.130.78433.21101.660.00
Proceedsfrom Stock Options44.3886.5561.060.006.130.00433.16101.660.00
Issuance or Reduction of Debt, Net-1.470.000.000.00-5.4949.5962.90-0.00
Change in Long Term Debt-1.470.000.000.000.00---0.00
Issuance of Long Term Debt0.000.000.000.000.00---0.00
Reduction of Long Term Debt-1.470.000.000.000.00---0.00
Net Financing Active Other Cash Flow-2.28-1.51-1.1673.10-1.32218.000.000.000.00
Other Financing Activities Uses-2.28-1.51-1.160.00-1.320.000.000.000.00
Cash from Financing Activities55.48150.9597.0573.88-0.90267.39494.97100.51-0.02
Exchange Rate Effect0.050.31-0.080.18-0.210.010.240.06-0.05
Net Change in Cash-42.8210.47-27.73-47.84-140.1027.35323.64-23.26-123.95
Free Cash Flow-99.03-141.44-124.70-121.90-139.00-236.81-169.53-121.94-122.31
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.0037.10-1.62-26.050.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments189.20219.11231.01261.34234.74264.56
Short Term Receivables28.4228.0431.0529.1222.9226.18
Inventories5.634.934.784.1818.0417.76
Other Current Assets15.339.639.9411.7011.4510.25
Total Current Assets238.58261.71276.77306.33287.15318.75
Net Property, Plant & Equipment1.001.101.201.301.391.49
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---0.79--
Other Assets16.2816.5713.5315.521.221.32
Total Assets255.86279.38291.50323.94289.76321.56
Short Term Debt Incl. Current Port. of LT Debt7.806.184.633.540.931.79
Accounts Payable5.5812.765.299.188.129.62
Other Current Liabilities64.7467.3957.7057.4552.9953.19
Total Current Liabilities78.1286.3367.6370.1662.0464.60
Long Term Debt108.30111.38112.03436.01456.50448.98
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.79--
Other Liabilities318.61309.87328.212.819.397.17
Total Liabilities505.04507.58507.87509.77527.94520.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-249.17-228.21-216.38-185.83-238.18-199.18
Total Shareholders Equity-249.17-228.21-216.38-185.83-238.18-199.18
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-249.17-228.21-216.38-185.83-238.18-199.18
Total Liabilities & Stockholders Equity255.86279.38291.50323.94289.76321.56
Book Value Per Share-1.95-1.79-1.70-1.48-2.11-1.77
Tangible Book Value Per Share-1.95-1.79-1.70-1.48-2.11-1.77
Full-Time Employees---193--
Price to Book Ratio-0.77-0.63-2.54-1.67-2.26-1.12
Return on Assets-29.78-32.25-48.57-44.16-52.26-49.02
Return on Invested Capital----2.56-18.76-22.68
Quick Ratio2.982.974.024.314.344.66
Current Ratio3.053.034.094.374.634.93

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-23.99-16.34-32.97-5.04-43.84-60.71
Depreciation--0.110.100.140.91
Other Funds (Non Cash)11.53-7.478.15-14.2211.6017.54
Funds from Operations-12.45-23.92-24.71-19.17-32.10-42.26
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-14.1812.30-5.01-11.870.2914.74
Cash from Operating Activities-26.64-11.62-29.71-31.03-31.81-27.52
Capital Expenditures0.000.00-0.030.00-0.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.680.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.030.69-0.00-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.600.120.1959.520.5798.06
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.600.120.1959.520.5798.06
Proceedsfrom Stock Options-0.600.00-0.0245.0044.940.00
Issuance or Reduction of Debt, Net-1.470.000.000.000.000.00
Change in Long Term Debt-1.470.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-1.470.000.000.000.000.00
Net Financing Active Other Cash Flow0.02-0.21-0.77-1.31-0.00-0.26
Other Financing Activities Uses0.02-0.21-0.77-1.31-0.00-0.26
Cash from Financing Activities-2.05-0.10-0.5858.210.5797.80
Exchange Rate Effect0.080.00-0.00-0.030.010.18
Net Change in Cash-28.61-11.71-30.3327.83-31.2370.44
Free Cash Flow-26.64-11.62-29.74-31.03-31.81-27.53

Revenue breakdown

License Revenues2025: 5.00M
Product2024: 69.28M 2025: 73.55M
Royalty2024: 1.56M 2025: 2.81M
EMEA2024: 1.56M 2025: 7.81M
United States2024: 69.28M 2025: 73.55M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.49%6.4M99.0M1.55M
2026-10-156.40%6.3M99.0M1.53M
2026-09-306.96%6.9M99.0M1.40M
2026-09-155.44%5.4M99.0M1.42M
2026-08-316.35%6.3M98.9M2.00M
2026-08-146.24%6.2M98.9M1.78M
2026-07-315.24%5.1M97.3M1.86M
2026-07-155.69%5.5M97.3M1.90M
2026-06-306.16%6.0M97.3M1.81M
2026-06-156.16%6.0M97.5M1.63M
2026-05-296.22%6.1M97.5M999.34K
2026-05-155.87%5.7M97.9M1.02M
2026-04-305.84%5.5M93.7M880.42K
2026-04-155.49%5.1M93.7M848.60K
2026-03-315.29%4.9M92.7M815.85K
2026-03-134.63%4.3M92.7M901.86K
2026-02-274.54%4.1M90.4M1.14M
2026-02-134.83%4.4M90.4M1.11M
2026-01-304.34%4.4M101.9M1.14M
2026-01-153.76%3.8M101.9M1.13M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.100.052.7032470.000.264-0.0120.001
call5.000.001.000.005.5050.000.000.192-0.0190.001
call7.500.003.800.006.5860.000.000.173-0.0210.001
put2.500.154.601.150.0002.000.00-0.742-0.0130.001
put5.001.005.400.000.0000.000.00-0.808-0.0180.001
put7.503.608.400.000.0000.000.00-0.827-0.0200.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-03S-4Registration statement for securities to be issued in business combination transactionsSEC
2026-10-29SCHEDULE 13GSEC
2026-10-138-KCurrent report2026-10-07SEC
2026-08-14SCHEDULE 13GSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-27SCHEDULE 13GSEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-028-KCurrent report2026-06-30SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-038-KCurrent report2026-06-03SEC
2026-06-028-KCurrent report2026-06-01SEC
2026-05-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-048-KCurrent report2026-05-04SEC
2026-04-24SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040018.19M4
2026-03001.44M2
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Nantahala Capital Management, LLC19.38%
Redmile Group, LLC9.06%
TCG Crossover Management, LLC8.96%
Prosight Management, LP6.15%
BlackRock, Inc.5.52%
AIGH Capital Management LLC3.39%
Point72 Asset Management, L.P.2.87%
MORGAN STANLEY2.40%
MILLENNIUM MANAGEMENT LLC2.28%
CITADEL ADVISORS LLC1.61%

Funds

Fund% owned
iShares Russell 2000 ETF2.15%
Fidelity Small Cap Index Fund0.91%
Oaktree Diversified Income Fund Inc.0.89%
iShares Russell 2000 Value ETF0.58%
iShares Biotechnology ETF0.53%
VANGUARD RUSSELL 2000 INDEX FUND0.48%
iShares Micro-Cap ETF0.28%
VANGUARD U.S. MOMENTUM FACTOR ETF0.25%
Schwab Small-Cap Index Fund0.20%
iShares Russell 2000 Growth ETF0.16%

OakChart. ADCT. Cached 15 minutes.